Grete Hogstad
Sales & Marketing bei PHOTOCURE ASA
Vermögen: 156 595 $ am 31.03.2024
Profil
Grete Hogstad is currently working as the VP-Strategic Marketing & Business Development at Photocure ASA since 2005.
She is also a member of the Association for Accessible Medicines.
Previously, she worked as a Director at Navamedic ASA, Alpharma, Inc., and Xellia Pharmaceuticals AS.
Ms. Hogstad completed her undergraduate degree from the University of Oslo and BI Norwegian Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PHOTOCURE ASA
0,11% | 31.12.2022 | 30 719 ( 0,11% ) | 156 595 $ | 31.03.2024 |
Aktive Positionen von Grete Hogstad
| Unternehmen | Position | Beginn |
|---|---|---|
| PHOTOCURE ASA | Sales & Marketing | 01.02.2005 |
Association for Accessible Medicines
 Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Grete Hogstad
| Unternehmen | Position | Ende |
|---|---|---|
Xellia Pharmaceuticals AS
 Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway. | Sales & Marketing | - |
| Alpharma, Inc. /Active Pharmaceutical Ingredients/ | Sales & Marketing | - |
| NAVAMEDIC ASA | Director/Board Member | - |
Ausbildung von Grete Hogstad
| University of Oslo | Undergraduate Degree |
| BI Norwegian Business School | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PHOTOCURE ASA | Health Technology |
| NAVAMEDIC ASA | Distribution Services |
| Private Unternehmen | 3 |
|---|---|
Association for Accessible Medicines
Association for Accessible Medicines Miscellaneous Commercial ServicesCommercial Services The Association for Accessible Medicines is an organization that aims to make generic and biosimilar medicines more accessible to those who need them. The organization is based in Arlington, VA. The non-profit company believes that increasing competition is the key to tackling the high cost of prescription drugs, rather than shifting costs among healthcare stakeholders. In 2022, generic and biosimilar prescription medicines saved $408 billion for the healthcare system overall, with more than $2.90 trillion saved over the past 10 years. The company was founded by Milan Puskar, Robert R. Grusky. David Gaugh has been the CEO of the company since 2012. | Commercial Services |
| Alpharma, Inc. /Active Pharmaceutical Ingredients/ | Health Technology |
Xellia Pharmaceuticals AS
Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway. | Health Technology |
